Long-term follow-up of lipid-lowering trials

Current Opinion in Lipidology
Chris J Packard, Ian Ford

Abstract

Most LDL-lowering trials are limited in duration while the disease process occurs over decades. It is informative, therefore, to evaluate the long-term effects of treatment by undertaking extended observation beyond the formal double-blind phase of intervention studies. The current review brings together the findings of major trials that have conducted such long-term follow-up. Extended observation of trial cohorts has reinforced the long-term safety of LDL-lowering therapy (with statins and other agents), with no evidence of late development of cancers or other adverse outcomes. Post-trial follow-up reveals also legacy benefits in terms of improved survival (due principally to decreased cardiovascular death rates), and lower hospitalization rates for cardiovascular disease. A number of trials report further risk reduction even after the formal intervention has ceased, and the appearance of delayed benefits such as reduced rate of heart failure. The perceived value of LDL lowering is enhanced significantly by the legacy benefits that persist after administration of treatment to individuals with established coronary heart disease or to those at high risk of developing disease. Safety, efficacy and the economics of intervention c...Continue Reading

References

Dec 1, 1986·Journal of the American College of Cardiology·P L CannerW Friedewald
Jan 1, 1994·Journal of Internal Medicine·J K HuttunenM H Frick
Apr 30, 2002·Lancet·UNKNOWN LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
Nov 30, 2002·Lancet·James ShepherdUNKNOWN PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk
Mar 10, 2005·The New England Journal of Medicine·John C LaRosaUNKNOWN Treating to New Targets (TNT) Investigators
Nov 24, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·H HoldaasUNKNOWN Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators
Apr 12, 2006·Archives of Internal Medicine·Leena TenkanenVesa Manninen
Oct 12, 2007·The New England Journal of Medicine·Ian FordUNKNOWN West of Scotland Coronary Prevention Study Group
Jan 8, 2008·European Heart Journal·Peter S SeverUNKNOWN ASCOT Investigators
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanDavid R Matthews
Jun 30, 2011·European Heart Journal·UNKNOWN European Association for Cardiovascular Prevention & RehabilitationUNKNOWN ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees
Aug 30, 2011·European Heart Journal·Peter S SeverUNKNOWN ASCOT Investigators
Jan 27, 2012·The New England Journal of Medicine·Jarett D BerryDonald M Lloyd-Jones
Nov 19, 2013·Journal of the American College of Cardiology·Neil J StoneUNKNOWN American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Nov 28, 2013·JAMA : the Journal of the American Medical Association·Jennifer G Robinson
Jan 23, 2014·European Heart Journal Cardiovascular Imaging·Rishi PuriStephen J Nicholls
Mar 8, 2014·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Han-lu LvDeng-feng Geng
Jul 12, 2014·The New England Journal of Medicine·Martin J LandrayJane Armitage
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators

❮ Previous
Next ❯

Citations

Jan 5, 2016·European Heart Journal·M John ChapmanUlf Landmesser
Aug 9, 2016·Progress in Cardiovascular Diseases·Sotirios Tsimikas
Oct 15, 2019·Current Opinion in Lipidology·Chris J Packard
Feb 29, 2020·Journal of Cardiovascular Pharmacology and Therapeutics·John B KostisWilliam J Kostis
Sep 28, 2017·European Heart Journal. Quality of Care & Clinical Outcomes·Jonathan A Tobert, David Preiss

❮ Previous
Next ❯

Software Mentioned

IT
ALERT
ALLHAT
PROSPER
IMPROVE
ASCOT
WOSCOPS
JUPITER

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.